| B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 (NCT05518383) | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 2022-05-25 |
| Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas (NCT04933617) | National Cancer Institute (NCI) | 2022-03-24 |
| Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma (NCT04491370) | New York Medical College | 2021-08-01 |
| Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma (NCT04739813) | National Cancer Institute (NCI) | 2021-07-09 |
| Immune Responses to COVID-19 Vaccination in Lymphoma Patients (NCT04858568) | University Hospital Southampton NHS Foundation Trust | 2021-03-11 |
| Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies (NCT04195633) | Fred Hutchinson Cancer Center | 2021-01-25 |
| Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T (NCT04488354) | Calibr, a division of Scripps Research | 2021-01-21 |
| Recommendations for the Treatment of Children With Burkitt's Lymphoma (NCT04425421) | French Africa Pediatric Oncology Group | 2020-11-01 |
| Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (NCT04545762) | C. Babis Andreadis | 2020-09-11 |
| CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies (NCT04450069) | Calibr, a division of Scripps Research | 2020-08-14 |
| Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies (NCT04191187) | H. Lee Moffitt Cancer Center and Research Institute | 2019-12-06 |
| Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda (NCT03864419) | Fred Hutchinson Cancer Center | 2019-10-24 |
| Mobile Health Case Management System for Reducing Pediatric Treatment Abandonment (NCT03677128) | Duke University | 2019-07-23 |
| A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) (NCT03833180) | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2019-03-14 |
| CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT (NCT03810196) | Children's Hospital of Philadelphia | 2019-03-01 |
| Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy (NCT03674411) | Masonic Cancer Center, University of Minnesota | 2019-01-02 |
| Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders (NCT03314974) | Masonic Cancer Center, University of Minnesota | 2018-03-30 |
| Long-term Follow-up Study of Patients Receiving CAR-T Cells (NCT03375619) | Medical College of Wisconsin | 2017-12-01 |
| CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma (NCT03298828) | Third Military Medical University | 2017-11-01 |
| Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies (NCT02991898) | Masonic Cancer Center, University of Minnesota | 2017-02-16 |
| Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies (NCT02483000) | Fred Hutchinson Cancer Center | 2017-02-01 |
| Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine (NCT02996773) | University of Arizona | 2016-11-29 |
| A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas (NCT02700022) | UNC Lineberger Comprehensive Cancer Center | 2016-10-01 |
| A Feasibility Study of Gallium-68 Citrate PET to Detect Aberrant MYC Proto-Oncogene, BHLH Transcription Factor (MYC) Protein Expression in Diffuse Large B-Cell Lymphoma (NCT02776891) | University of California, San Francisco | 2016-06-13 |
| Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL (NCT02393157) | New York Medical College | 2015-08-21 |
| ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies (NCT02362035) | Acerta Pharma BV | 2015-02-20 |
| Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma (NCT01943682) | Children's Hospital Medical Center, Cincinnati | 2013-09-01 |
| Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas (NCT01793233) | Children's Oncology Group | 2013-06-17 |
| A Phase I Trial of AZD3965 in Patients With Advanced Cancer (NCT01791595) | Cancer Research UK | 2013-04-23 |
| A Safety Study of SGN-CD19A for B-Cell Lymphoma (NCT01786135) | Seagen Inc. | 2013-02-01 |
| A Safety Study of SGN-CD19A for Leukemia and Lymphoma (NCT01786096) | Seagen Inc. | 2013-02-01 |
| Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT01529827) | Roswell Park Cancer Institute | 2012-02-28 |
| Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (NCT01363128) | M.D. Anderson Cancer Center | 2011-07-12 |
| A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy (NCT01184885) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2010-07-01 |
| Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia (NCT01109069) | Pharmacyclics LLC. | 2010-06-01 |
| Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT01028716) | Fred Hutchinson Cancer Center | 2010-05-19 |
| Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer (NCT01053494) | Wake Forest University Health Sciences | 2010-04-01 |
| Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma (NCT01092182) | National Cancer Institute (NCI) | 2010-03-25 |
| Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604) (NCT00864227) | Medical College of Wisconsin | 2008-12-01 |
| Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603) (NCT00849147) | Medical College of Wisconsin | 2008-10-01 |
| Coproporphyrine Isomers and Methotrexate Elimination (NCT00822432) | Assistance Publique - Hôpitaux de Paris | 2007-10-01 |
| Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT01093586) | Case Comprehensive Cancer Center | 2007-09-01 |
| Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease (NCT00719888) | Fred Hutchinson Cancer Center | 2005-11-18 |
| Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma (NCT00126191) | Dana-Farber Cancer Institute | 2005-07-01 |
| Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas (NCT00183976) | University of Southern California | 2005-04-01 |
| LMBA02 Protocol for Patients With a Burkitt Lymphoma (NCT00180882) | Gustave Roussy, Cancer Campus, Grand Paris | 2004-10-01 |
| Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL (NCT00180895) | Gustave Roussy, Cancer Campus, Grand Paris | 2004-06-01 |
| Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma (NCT01290120) | Northern Italy Leukemia Group | 2002-11-01 |
| Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma (NCT00001337) | National Cancer Institute (NCI) | 1993-05-08 |
| Pilot Protocol for the Treatment of Patients With Small Non-Cleaved and Diffuse Large Cell Lymphomas (NCT00001237) | National Cancer Institute (NCI) | 1989-03-01 |
| High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma (NCT01177371) | Case Comprehensive Cancer Center | 1988-03-01 |